Actively Recruiting
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
Led by Massachusetts General Hospital · Updated on 2025-06-15
80
Participants Needed
1
Research Sites
195 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE). Hypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.
CONDITIONS
Official Title
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 60#8805;18 years old
- Confirmed Pulmonary Embolism (PE) on imaging within 24 hours prior to enrollment
- New symptom onset and/or worsening symptoms within 72 hours
- Confirmation of right ventricular dysfunction (RVD) by clinician
- Oxygen saturation 60#8805;90% while breathing room air
You will not qualify if you...
- Hemodynamic instability
- Use of vasopressors or mechanical circulatory support
- Planned use of thrombolytics or plan for embolectomy
- Oxygen saturation <90% while breathing room air
- New onset arrhythmia
- History of pulmonary hypertension, severe COPD requiring home oxygen or chronic steroid use, hypoventilation syndrome requiring CPAP or BiPAP, or congestive heart failure with LV ejection fraction <40% or chronic oxygen therapy
- Known pregnancy
- Vasodilator medication used in the past 24 hours
- Symptom onset 63;72 hours
- Inability to wear a face mask
- Inability to obtain adequate baseline echocardiogram
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
C
Christopher Kabrhel, MD, MPH
CONTACT
B
Blair Alden Parry, CCRC, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here